WASHINGTON — President Barack Obama is directing the U.S. Food and Drug Administration to take steps to reduce drug shortages, action he says will help stop a “slow-rolling problem” that puts patients at risk and raises the potential for price gouging.
Obama signed an executive order on Monday instructing the FDA to take action in three areas: broadening its reporting of potential drug shortages; accelerating reviews of applications to change production of drugs facing potential shortages; and giving the Justice Department more information about possible instances of collusion or price gouging.
The executive action is part of a larger push by the White House to portray Obama, who is facing re-election in November 2012, as an effective counterpoint to congressional Republicans blocking his jobs legislation.Last week, he issued three other executive orders
Patient deaths have been blamed on the shortages, which tend to affect cancer drugs, anesthetics, drugs used in emergency medicine, and electrolytes needed for intravenous feeding. Hospitals have been forced to buy from secondary suppliers at huge markups. Surgeries and cancer treatments have been delayed.
“Even though the FDA has successfully prevented an actual crisis, this is one of those slow-rolling problems that could end up resulting in disaster for patients and health care facilities all over the country,” Obama said.
The president ordered the new steps without congressional approval, saying his administration refused to wait for lawmakers to act on similar legislation pending on Capitol Hill.
Obama said the White House would continue to push lawmakers to pass bipartisan legislation to prevent drug shortages, but said “we can’t wait for action on the Hill, we’ve got to go ahead and move forward.”
The FDA reported 178 drug shortages last year, and the agency says it continues to see an increase in shortages this year. Major causes of drug shortages are said to be quality or manufacturing problems, or delays in receiving components from suppliers. Drug makers also discontinue certain drugs in favor of newer medications that are more profitable. The FDA does not have authority to force drug makers to continue production of a drug.